Understanding the Technology Segmentation: NGS, PCR, and Microarrays in the Genomics In Cancer Care Market
Description: A technical breakdown of the different technologies—Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Microarrays—and their respective roles in the Genomics In Cancer Care Market.
The technology segment forms the backbone of the Genomics In Cancer Care Market, enabling all diagnostic and research activities. Next-Generation Sequencing (NGS) is the dominant technology due to its capability for comprehensive genomic profiling (CGP). Its high throughput and ability to detect various mutation types simultaneously make it the tool of choice for tumor profiling, which is essential for identifying actionable targets for personalized therapy. NGS is central to modern cancer research, covering whole-genome, whole-exome, and transcriptome sequencing.
Polymerase Chain Reaction (PCR), while a more established technology, remains a major revenue driver, particularly the digital PCR (dPCR) and quantitative PCR (qPCR) variants. PCR is highly valuable for its speed, sensitivity, and cost-effectiveness in performing targeted assays, such as detecting specific single-gene mutations, monitoring minimal residual disease (MRD), and validating NGS results. Its simplicity and robust nature ensure its continued widespread use in clinical laboratories.
Microarrays are also perceiving swift development. These devices allow researchers to measure the expression levels of thousands of genes simultaneously. In cancer care, microarrays are integral for gene expression profiling, which helps in classifying tumor subtypes and predicting patient prognosis. While NGS offers a more comprehensive view, microarrays remain cost-effective for large-scale screening and initial gene expression studies. The diverse and complementary roles of NGS, PCR, and microarrays ensure that the technology segment of the Genomics In Cancer Care Market continues to be dynamic and highly innovative.